In CRC patients who received either capecitabine or capecitabine combined with oxaliplatin post-surgery, positive LC3 expression correlated with worse OS relative to non-expressing patients (χ2 = 4.216, P = 0.040, Fig. 6). This evidence concerns the gene MAP1LC3A and colorectal carcinoma.